Previous trials on the effectiveness of genotype-guided warfarin dosing vs. conventional dosing have been inconclusive. We conducted a systematic review and meta-analysis of randomized trials comparing genotype-guided to conventional dosing strategies.
Introduction
Warfarin is one of the most commonly prescribed drugs, accounting for more than 35 million prescriptions in the United States alone [1] . However, it is also responsible for more iatrogenic accident and emergency department visits in older patients compared with other medications [2, 3] . This may be related to over-or underdosing because of wide interindividual variability in dosing requirements. To optimize anticoagulation control, the use of genetic-based algorithms, collectively termed 'genotype-guided dosing', has been devised. However, previously published randomized controlled trials (RCTs) comparing the effects of genotypeguided dosing against conventional dosing (either fixed dosing or clinically guided dosing) strategies [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , and even their subsequent meta-analyses, have yielded conflicting results [15] [16] [17] [18] [19] [20] [21] . A meta-analysis published in 2015, which pooled the evidence from 11 RCTs with trial sequential analysis [21] , reported a shorter time to reach the first therapeutic or stable international normalized ratio (INR), and improvements in markers of anticoagulation control such as the time in therapeutic range (TTR) and the number of patients with an out-of-range INR, although this did not translate into better clinical outcomes of reducing bleeding, thromboembolism or mortality.
Since the publication of that study, six additional trials have been published on this issue [22] [23] [24] [25] [26] [27] , with the most recent three showing conflicting results. For example, an RCT conducted in 2015 on nonvalvular atrial fibrillation patients reported no significant difference in TTR or in the number of patients with an out-of-range INR [22] . Similarly, in a group of Han Chinese individuals, there was no difference in TTR, excessive anticoagulation or adverse events between the genotype-guided and optimal clinical care arms [27] . By contrast, the recently published Genetic Informatics Trial of Warfarin to Prevent Deep Vein Thrombosis (GIFT) in patients receiving warfarin at the time of elective hip or knee arthroplasty reported significant benefits with genotypeguided dosing when compared with clinically-guided dosing [25] . In GIFT, genotype-guided warfarin dosing increased the TTR, and reduced the combined risk of major bleeding, an INR of ≥4, venous thromboembolism or death. Given these new findings, we conducted a systematic review and meta-analysis of all RCTs to evaluate the benefits and complication rates in genotype-guided dosing vs. conventional dosing strategies.
Methods

Search strategy, and inclusion and exclusion criteria
The systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [28] . PubMed and the Cochrane Library were searched for RCTs that compared the efficacy in genotype-guided warfarin dosing compared with conventional dosing strategies. The following search terms were used for PubMed: [genotype AND warfarin AND randomized trial]. For the Cochrane Library, the following terms were used: [genotype AND warfarin]. The search period was from 1966 to 23 October 2017 for Pubmed, and 1996 to 23 October 2017 for the Cochrane Library, with no language restrictions. The following inclusion criteria were applied: (i) RCTs in humans; and (ii) studies comparing the outcomes for genotype-guided vs. conventional warfarin dosing strategies. Reference lists of included studies, and of previous meta-analyses identified, were searched. No additional studies were found. Given the recently published PRISMAcompliant systematic review and meta-analysis studies, a more robust search strategy was used than had been used in previous meta-analyses. The 2015 Tang meta-analysis [21] was performed using the [(genotype OR polymorphism OR gene OR allele OR variant OR mutation OR single-nucleotide polymorphism) AND (algorithms OR regimen OR model OR strategy)] AND (warfarin OR coumarin OR anticoagula*) search terms. We used the same search terms in PubMed between 1 February 2017 and 31 March 2018, yielding an additional 128 studies. This failed to identify any further relevant studies ( Figure S1 ). Quality assessment of RCTs was performed using the Cochrane Risk Assessment Tool ( Figures S2 and S3 ).
Data extraction
Data from the different studies were entered in Microsoft Excel. All publications extracted from the search strategy were assessed for compliance with the inclusion criteria. In the present meta-analysis, the extracted data elements consisted of: (i) the surname of the first author and year of publication; (ii) the target INR; (iii) the duration of follow-up; (iv) the characteristics of the genotype-guided and control groups, including sample size, gender and age; (v) the genes tested and dosing algorithm for the genotype-guided group; and (vi) the dosing algorithm and whether fixed-dose or clinical information-guided strategy was used for the control group. The search of the two databases was conducted by G.T. The search results were then retrieved and screened independently by G.T. and M.G. Any disagreements were to be brought to the attention of a third reviewer (T.L.). However, this was not required as both reviewers arrived at the same list of RCTs for inclusion in the meta-analysis.
Endpoints and statistical analysis
The a priori predefined endpoints for the meta-analysis were: (i) time to first therapeutic INR; (ii) time to first stable INR; (iii) TTR; (iv) number of patients with excessive anticoagulation, defined as INR ≥4; (v) number of patients with bleeding; (vi) number of patients with thromboembolism; and (vii) number of mortalities. For time to first therapeutic INR, time to first stable INR and TTR, the mean difference between the genotype-guided dosing and conventional dosing strategies was extracted or calculated. For INR ≥4, bleeding, thromboembolism and mortality, risk ratios (RRs) were calculated. When the data concerning a particular endpoint were not available, they were obtained from previously published meta-analyses.
Heterogeneity across studies was assessed using the I 2 statistic from the standard chi-square test, which describes the percentage variability in the effect estimates resulting from heterogeneity. I 2 >50% was considered to reflect significant statistical heterogeneity, and in such cases the random-effects model using the inverse variance approach was used. Otherwise, the fixed-effects model was used. To explore the potential sources of the heterogeneity, subgroup analysis based on the type of warfarin dosing for the control group (fixed dose and clinical information guided) was performed. Funnel plots showing standard errors against the mean difference or against the logarithms of the RRs were constructed. Egger's test was used to detect publication bias.
Results
A quorum diagram detailing the above search terms with inclusion and exclusion criteria is depicted in Figure 1 . A total of 76 and 94 studies were retrieved from PubMed and the Cochrane Library, respectively. However, 152 studies did not meet the inclusion criteria. Therefore, a total of 18 trials were included in the present meta-analysis [4-14, 22-27, 29] . The baseline characteristics of these studies are listed in Table 1 . The meta-analysis included 2626 patients in the genotypeguided dosing arm (mean age 63.3 ± 5.8 years; 46% male) and 2604 patients in the conventional dosing arm (mean age 64.7 ± 6.1 years; 46% male). The mean follow-up duration was 64 days. For the control group, two conventional dosing strategies were used. The first was fixed dosing, where the patients received a fixed dose for a fixed number of days. This varied from 2.5 mg to 6 mg for 3-7 days, 10 mg on day 1, 5 mg on day 2 and 5 mg on day 3 regimens were also used. The lower doses were used in Chinese populations, where warfarin requirements are lower. The second dosing strategy used was clinical information-guided dosing, for which the different definitions are illustrated in Table 1 . This involved the use of regression models based on different clinical parameters such as age, gender, body surface area and valve status. For the genotype-guided group, 12 different algorithms were described in the 18 trials, incorporating the cytochrome P450 (CYP) 2C9, vitamin K epoxide reductase complex subunit 1 (VKORC1) and CYP4F2 polymorphisms to determine the warfarin dose (Table S1 ). Quality assessment of RCTs was performed using the Cochrane Risk Assessment Tool ( Figures S2 and S3) . Overall, risk of bias assessment could be conducted for 16 of the 18 trials conducted, whereas the remaining two studies were conference abstracts [24, 29] , which could not be judged on their quality owing to the lack of information reported. One study [6] was deemed to be of low quality, whereas the remaining 15 studies generally showed high-quality study designs for reducing the risk of bias. Specifically, for random sequence generation, nine of the 18 trials included a low risk of bias. Similarly, for allocation concealment, only eight trials had an appropriate design to reduce selection bias. Nevertheless, to reduce performance bias, 12 trials had described proper blinding of participants and research personnel. For blinding of outcome assessment, most studies did not clearly illustrate an appropriate method, except for two trials, which had a low risk of attrition bias. On selective reporting, 15 of the 18 trials had appropriately described their data on their different endpoints, which therefore had a low risk of reporting bias. Funnel plots showing standard errors against the mean difference or against the logarithms of the RRs are shown in Figures S4 and S10.
Time-to-first therapeutics INR and stable INR
Seven studies provided information on the time taken to reach the first therapeutic INR [6, 9, 23, [25] [26] [27] 29] , but only three of these provided sufficient information for the calculation of mean difference values [6, 9, 26] (Figure 2A , top). It was defined by Borgman et al. [9] as 'the time interval in days from the first warfarin dosage to the first time interval where the INR remains within the predefined acceptable range (INR 1.8 to 3.2) for a minimum of 4 consecutive days'. By contrast, Caraco et al. [6] defined stable anticoagulation as 'two consecutive INR values, 7 days apart, were within the therapeutic range, without any intervening dose alteration'. Jin et al. [26] defined it as 'INR values maintained in the range of
Figure 1
Flowchart of the database search and study selection process 2-3 for at least three times (≥7 days) continuously'. Our meta-analysis showed a significantly shorter time to reach the first therapeutic INR in the genotype-guided dosing group when compared with controls, all of which used fixed dosing (mean difference 2.6 days, standard error 0.3 days; P < 0.0001; I 2 0%; Figure 2A , top). Egger's test demonstrated no significant asymmetry (intercept 0.9, t-value 1.9; P > 0.05; Figure S4 ). Subgroup analysis based on ethnicity showed that the mean differences remained statistically significant for each ethnicity (Figure 2A, bottom) . For the time taken to reach a stable INR, four studies provided the median [8, 10, 14, 23] and six studies the mean [6, 10, 11, 22, 26, 27] . Of the latter six studies, one was excluded because the standard deviation or another measure of dispersion was not available [27] (Figure 2B , top). Our meta-analysis of the remaining five studies showed a shorter time to reach a stable INR with the genotype-guided dosing group (mean difference 5.9 days, standard error 2.0 days; P < 0.01; I 2 94%). Egger's test demonstrated no significant asymmetry (intercept 0.6, t-value 0.2; P > 0.05; Figure S5 ). Of the five studies, four used a fixed-dosing regimen for the control group, and the mean difference remained statistically significant on subgroup analysis ( Figure 2B , top). Subgroup analysis for ethnicity showed that the mean difference remained significant for Caucasian and Chinese subjects, but not in the study with both Caucasian and African subjects ( Figure 2B , bottom).
Percentage TTR and excessive anticoagulation
Fourteen of the 18 trials reported TTR values [4-9, 11, 12, 14, 22-25, 27 ] but one study [24] was excluded as it did not report the standard error, standard deviation or confidence interval. Of the 13 studies, five reported significantly higher TTRs in genotype-guided therapy compared with conventional dosing strategies, whereas the remaining studies reported no difference between the two groups ( Figure 3A, top) . Nevertheless, our metaanalysis showed that genotype-guided warfarin dosing significantly increased TTR compared with conventional dosing strategies (mean difference 3.1%, standard error 1.2%; P < 0.05; I 2 80%). Egger's test demonstrated no significant asymmetry (intercept 0.2, t-value 0.2; P > 0.05; Figure S6 ). Subgroup analysis showed that genotype-guided dosing produced a greater TTR than fixed-dose regimens (mean difference 7.4%, standard error 2.0%; P < 0.0001; I 2 71%) ( Figure 3A, top) . By contrast, no significant difference in TTRs was observed between genotype-guided dosing and clinical information-guided regimens (mean difference 0.5%, standard error 1.5%; P = 0.73; I 2 55%). Subgroup analysis based on ethnicity showed that TTRs remained significantly different between both groups for Caucasian, Caucasian and African, and Chinese individuals, with I 2 taking values of 84%, 54%, 0%, respectively ( Figure 3A, bottom) . Moreover, 13 of the 18 trials [4-9, 11, 12, 14, 22, 24, 25, 27] reported the number of individuals with excessive anticoagulation, defined as INR ≥4, and the total number of individuals in each group. Of these, two reported a reduction in the RR for excessive anticoagulation in genotype-guided therapy compared with conventional dosing strategies, whereas 11 studies reporting no significant difference ( Figure 3B, top) . Our overall meta-analysis demonstrated that genotype-guided warfarin dosing was associated with a lower risk of excessive anticoagulation [RR 0.87; 95% confidence interval (CI) 0.78, 0.98; P < 0.05; I 2 0%]. Egger's test demonstrated no significant asymmetry (intercept 0.3, t-value 0.6; P > 0.05; Figure S7 ). Subgroup analysis remained statistically significant when compared with the fixed-dose (RR 0.82; 95% CI 0.68, 0.99; P < 0.05; I 2 0%) but not with the clinical information-guided (RR 0.91; 95% CI 0.78, 1.06; P = 0.22; I 
Bleeding, thromboembolism and mortality
Fourteen of the 18 trials reported bleeding events [4, 6-8, 11, 12, 14, 22-27, 29 ], but one [22] was excluded from the analysis owing to zero events in both groups. Two trials reported a
Figure 2
Panel A shows the mean difference in time to first therapeutic international normalized ratio (INR) based on control group dosing regimen (top) or ethnicity (bottom). Panel B shows the mean difference in time to first stable INR based on control group dosing regimen (top) or ethnicity (bottom). CI, confidence interval significant reduction in bleeding using genotype-guided dosing, whereas the other trials did not report significant differences ( Figure 4A , top). Our overall meta-analysis showed that genotype-guided dosing was associated with a lower risk of bleeding (RR 0.82; 95% CI 0.69, 0.98; P < 0.05; I 2 31%).
Egger's test demonstrated significant asymmetry (intercept À1.4, t-value 4.1; P < 0.05; Figure S8 [6, 22, 27] were excluded because zero events were reported for both genotype-guided dosing and conventional dosing groups. None of the remaining studies reported a significant difference in thromboembolism events ( Figure 4B, top) , which was confirmed by our metaanalysis (RR 0.84; 95% CI 0.56, 1.26; P = 0.40; I 2 0%). Egger's test demonstrated no significant asymmetry (intercept À0.4, t-value 0.9; P > 0.05; Figure S9 ). Subgroup analyses comparing against the fixed-dose (RR 0.27; 95% CI 0.03, 2.38; P = 0.24; I 2 0%) or clinical information-guided (RR 0.87; 95% CI 0.58, 1.32; P = 0.53; I 2 0%) regimen did not significantly alter the findings (Figure 4B, top) . Subgroup analyses based on ethnicity also did not alter our results ( Figure 4B, bottom) . It was possible to calculate the number of patients needed to be genotyped in order to reduce the number of adverse events by one, based on the absolute risk difference. This was estimated to be only 40 patients for major bleeding but 238 for thromboembolism.
Mortality was reported in seven trials [8, 11, 12, 14, [23] [24] [25] ], but one [25] was excluded from further analysis because of zero events in both groups. Of the remaining studies, none reported a significant difference in mortality between genotype-guided dosing and conventional dosing groups ( Figure 5, top) , which was confirmed by our meta-analysis (RR 1.16; 95% CI 0.46, 2.90; P = 0.76; I 2 0%). Egger's test demonstrated no significant asymmetry (intercept À1.1, t-value 0.8; P > 0.05; Figure S10 ). 
Discussion
The main findings of the present meta-analysis were that, compared with conventional dosing strategies, genotypeguided warfarin dosing significantly: (i) shortened the time to first therapeutic INR by 2. Warfarin has been one of the most commonly prescribed anticoagulant medications since its approval in 1954, although it may have been overtaken by non-Vitamin K oral anticoagulants [30] . Inactivation of warfarin occurs when it is metabolized to the 7-hydroxy metabolite by CYP2C9 [31] . Polymorphisms in CYP2C9 are known to reduce the activity of the enzyme, leading to less effective warfarin inactivation [32] . Moreover, polymorphisms in both the VKORC1 and CYP2C9 genes contribute to the interindividual variability in dosing requirements [33] and patients' responses to warfarin [34] . Therefore, there has been significant interest in establishing whether genotype-guided dosing therapy will improve INR control and clinical outcomes for patients on warfarin.
Figure 4
Panel A shows the risk ratios for comparing the number of individuals with bleeding symptoms between the genotype-guided warfarin dosing and conventional dosing groups based on the control group dosing regimen (top) or ethnicity (bottom). Panel B shows the risk ratios for comparing the number of individuals with thromboembolism, based on the control group dosing regimen (top) or ethnicity (bottom). CI, confidence interval Previous RCTs comparing the effectiveness of genotypeguided dosing and conventional dosing strategies, and evenmeta-analyses of these trials, have been inconclusive [15] [16] [17] [18] . Nevertheless, a subsequent meta-analysis of 11 RCTs with trial sequential analysis has demonstrated improvements in the biochemical parameters of INR control and TTR values but limited clinical utility with genotype-guided dosing [21] . However, since its publication, an additional seven trials have been published. Of these newer trials, GIFT has been the largest to date, with 1597 subjects. This trial contributed approximately one-third to the cohort included in the current meta-analysis, and reported that genotypeguided dosing prevented more adverse outcomes than clinically guided dosing in patients undergoing hip and knee surgery. In orthopaedic surgery, surgeons often have more time to obtain genotype data and use this information to plan for the surgery. By contrast, physicians who encounter patients with atrial fibrillation or venous thromboembolism often have little time to obtain genotype data before prescribing anticoagulants.
In our updated meta-analysis, our significant findings were that both biochemical measures of warfarin therapy were improved, and bleeding complications reduced. The endpoints were chosen as these parameters are critical for guiding the decision-making process in clinical practice. For example, both time to first therapeutic INR and time to stable INR can guide clinicians in deciding on an appropriate follow-up duration and frequency. By contrast, TTR, INR ≥4 and risks of complications are important for resource allocation at the population level. The effect of genotype-guided warfarin dosing compared with conventional dosing on TTR is convincing and is clinically important. The significant difference in TTR when a clinical information-guided warfarin dosing regimen is used in the conventional arm is striking.
Two of the studies included in the meta-analysis genotyped only for CYP2C9 variants [4, 6] . The Clarification of Optimal Anticoagulation through Genetics (COAG) trial genotyped for CYP2C9*2 and *3 variants only, and not for other CYP2C9 variants [12] . This is important because other CYP2C9 variants are found more frequently than CYP2C9*2 and *3 in African Americans, who constituted nearly one-third of the study population. Therefore, the advantages of genotype-guided warfarin dosing could be diminished in populations with African ancestry. Nevertheless, in the COAG trial, TTR was improved, excessive anticoagulation was reduced and the number of adverse events was reduced significantly. Consequently, in our meta-analysis this had little impact on the overall pooled effect estimates for these endpoints.
Figure 5
Risk ratios for comparing the mortality between the genotype-guided warfarin dosing and conventional dosing groups based on control group dosing regimen (top) or ethnicity (bottom). CI, confidence interval There are several considerations on the practicality of utilizing genotype-guided warfarin dosing. All of the included studies had applied complex proprietary algorithms for genotype testing to determine the suitable warfarin dose. Currently, it is unclear which algorithm is the best because no direct comparisons have been made. Currently, at least for physicians, it is difficult to take the time for genotype-guided dosing to guide warfarin treatment during their busy workday, especially when a patient presents with acute venous thromboembolism or atrial fibrillation, when anticoagulation needs to be started immediately. This may not be the case for orthopaedic surgery, for which more time is available for the planning of surgery and anticoagulation. It may well be that there are adequate time and resources for acquiring the genotype of patients in clinical trials or in university hospitals. The situation is different for doctors who are working in the average clinic or hospital without significant resources that can be used for such testing. Nevertheless, a study has examined the procedural feasibility of a pharmacist-led interdisciplinary service for providing genotype-guided warfarin dosing for hospitalized patients newly starting on warfarin [35] . When these tools were embedded into electronic health records, the majority of genotypes were available before the second warfarin dose, and good adherence to genotypeguided dose recommendations by the medical staff was observed.
We estimated that genotyping is needed for 40 individuals in order to decrease the number of major bleeding events by one. By contrast, genotyping is needed for 238 individuals to reduce the number of thromboembolic events by one. These findings suggest that genotype-guided warfarin dosing could be worthwhile for individuals who are at high risk of bleeding. A related key issue is whether the benefits of genotype-guided dosing are cost-effective. The widespread and increasing use of non-VKAs is likely strongly to diminish the impact of genotype-driven dosing for vitamin K anticoagulation. For patients who are prescribed warfarin, the cost of genotyping is relatively modest and likely to be much less costly than the costs for hospital admissions, long stays, and medical or interventional treatment due to bleeding. As cost-effectiveness may also vary with the baseline risk of bleeding of the patients concerned, depending on the comorbidities, this issue requires formal health economic analysis in future studies, to determine the subset of patients on warfarin for whom genotype-guided dosing is cost-effective [36] . Indeed, analyses of cost-effectiveness have been conducted using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation [37] . Based on a Markov state transition decision model with effectiveness measured by quality-adjusted life-years, it was shown that warfarin-related genotyping is unlikely to be cost-effective for typical patients but may be cost-effective in those at high risk of haemorrhage who will be started on warfarin therapy. Recent work has demonstrated its costeffectiveness in other conditions, such as mechanical heart valve replacement [38] .
In 11 of the 18 trials, the genotype-guided therapy arm was compared with a fixed-dosing strategy in the standard care arm. In these studies, it is difficult to attribute the beneficial effects entirely to genotyping because patients in this group also benefited from the algorithms or regression models using clinical information, which also contributed to the accuracy of warfarin dosing. Therefore, the benefits of genotype-guided therapy alone are better estimated by comparing with the remaining seven studies using the clinical information-guided approach in the standard care arm. There was no apparent improvement in TTR, excessive anticoagulation, risk of thromboembolism or mortality between the genotype-guided and the clinical informationguided groups, although there may be a benefit in reducing the number of bleeding events. From the previous metaanalyses [15] [16] [17] [18] [19] [20] [21] , only three had performed subgroup analyses based on the dosing regimen in the control group [18, 20, 21] . All three of these meta-analyses demonstrated no significant improvement in either biochemical parameters of INR control or the clinical endpoints of bleeding and thromboembolism events in the genotype-guided warfarin dosing group when compared with the clinical informationguided group using an equation-based approach.
Strengths and limitations
The current study had many strengths. It was the largest meta-analysis of randomized trials to date, including 5230 participants from 18 trials. No heterogeneity or a low level of heterogeneity was observed for our meta-analyses on excessive anticoagulation, bleeding, thromboembolism and mortality. Heterogeneity remained low, even when different types of control groups (fixed dosing and clinical information-guided dosing) were analysed together, indicating the appropriateness of pooling these studies.
However, several limitations inherent in the present meta-analysis should be noted. Firstly, significant heterogeneity was observed for the time to stable INR analysis. Similarly, the meta-analysis of TTR showed a high level of heterogeneity, which was only partially accounted for when fixed dosing and clinical information-guided dosing were analysed separately. Some of the heterogeneity may have been clinical, as a result of different patient populations studied-for example, with different indications for anticoagulation. As described above, any small benefits in lowering the risk of bleeding can be magnified in orthopaedic surgery because of the presence of open surgical wounds. In addition, our meta-analysis focused on only one coumarin anticoagulant, warfarin, and no others. For example, neither acenocoumarol nor phenprocoumon, which may be more commonly prescribed in some countries, were included. Further analyses will be needed to establish whether genotypeguided dosing is also better than conventional dosing strategies for such agents. Moreover, the mean follow-up duration was 64 days. Although this is sufficient for evaluating the time to first therapeutic INR and time to stable INR, it cannot provide the full picture in terms of clinical outcomes. Furthermore, there appears to be considerable heterogeneity among the genotype testing regimens. Finally, although differences in bleeding rates could be detected in our meta-analysis, the study may not have been powered sufficiently to detect differences in thromboembolism or mortality. Future work could also analyse whether genotype-guided warfarin dosing is similarly effective in the perioperative periods in orthopaedic settings as compared with other clinical indications.
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